Neose Technologies Inc. is raising $28 million in a public offering to fund ongoing development activities, including preclinical and clinical evaluation of its two lead protein products. (BioWorld Today)
A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today)
A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today)
